IL274149B2 - Sustained release formulations for intra-articular applications - Google Patents

Sustained release formulations for intra-articular applications

Info

Publication number
IL274149B2
IL274149B2 IL274149A IL27414920A IL274149B2 IL 274149 B2 IL274149 B2 IL 274149B2 IL 274149 A IL274149 A IL 274149A IL 27414920 A IL27414920 A IL 27414920A IL 274149 B2 IL274149 B2 IL 274149B2
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
oxabicyclo
dichlorophenyl
pyridin
heptane
Prior art date
Application number
IL274149A
Other languages
English (en)
Hebrew (he)
Other versions
IL274149A (en
IL274149B1 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL274149A publication Critical patent/IL274149A/en
Publication of IL274149B1 publication Critical patent/IL274149B1/en
Publication of IL274149B2 publication Critical patent/IL274149B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL274149A 2017-11-10 2018-11-08 Sustained release formulations for intra-articular applications IL274149B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584589P 2017-11-10 2017-11-10
US201862743864P 2018-10-10 2018-10-10
PCT/IB2018/058788 WO2019092637A1 (en) 2017-11-10 2018-11-08 Extended release formulations for intra-articular applications

Publications (3)

Publication Number Publication Date
IL274149A IL274149A (en) 2020-06-30
IL274149B1 IL274149B1 (en) 2023-10-01
IL274149B2 true IL274149B2 (en) 2024-02-01

Family

ID=64402238

Family Applications (2)

Application Number Title Priority Date Filing Date
IL305541A IL305541A (en) 2017-11-10 2018-11-08 Extended release formulations for intra-articular applications
IL274149A IL274149B2 (en) 2017-11-10 2018-11-08 Sustained release formulations for intra-articular applications

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL305541A IL305541A (en) 2017-11-10 2018-11-08 Extended release formulations for intra-articular applications

Country Status (23)

Country Link
US (1) US20210177824A1 (enExample)
EP (1) EP3706710B1 (enExample)
JP (1) JP7284750B2 (enExample)
KR (1) KR20200087138A (enExample)
CN (1) CN111278410A (enExample)
AU (1) AU2018364685B2 (enExample)
CA (1) CA3075722A1 (enExample)
CL (1) CL2020001156A1 (enExample)
DK (1) DK3706710T3 (enExample)
ES (1) ES2981903T3 (enExample)
FI (1) FI3706710T3 (enExample)
HR (1) HRP20240808T1 (enExample)
HU (1) HUE066971T2 (enExample)
IL (2) IL305541A (enExample)
LT (1) LT3706710T (enExample)
MX (2) MX2020004477A (enExample)
PL (1) PL3706710T3 (enExample)
PT (1) PT3706710T (enExample)
RS (1) RS65659B1 (enExample)
SA (1) SA520411881B1 (enExample)
SI (1) SI3706710T1 (enExample)
TW (2) TW202400164A (enExample)
WO (1) WO2019092637A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12257243B2 (en) 2018-12-06 2025-03-25 Novartis Ag 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
KR20220076371A (ko) * 2020-11-30 2022-06-08 주식회사 엘지화학 캐스파제 저해제를 함유하는 주사용 조성물 및 이의 제조 방법
KR20240133027A (ko) 2023-02-28 2024-09-04 주식회사 포스테라헬스사이언스 올리고펩타이드를 포함하는 서방형 입자 및 이의 제조 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012172072A1 (en) * 2011-06-17 2012-12-20 Ares Trading S.A. Freeze-dried formulations of fgf-18
US20170239227A1 (en) * 2014-05-13 2017-08-24 Novartis Ag Compounds and compositions for inducing chondrogenesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012172072A1 (en) * 2011-06-17 2012-12-20 Ares Trading S.A. Freeze-dried formulations of fgf-18
US20170239227A1 (en) * 2014-05-13 2017-08-24 Novartis Ag Compounds and compositions for inducing chondrogenesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D RAMYA DEVI ET AL,, POLOXAMER: A NOVEL FUNCTIONAL MOLECULE FOR DRUG DELIVERY AND GENE THERAPY, 1 August 2013 (2013-08-01) *

Also Published As

Publication number Publication date
HUE066971T2 (hu) 2024-09-28
US20210177824A1 (en) 2021-06-17
LT3706710T (lt) 2024-07-10
TW202400164A (zh) 2024-01-01
MX2023007036A (es) 2023-06-28
SA520411881B1 (ar) 2024-01-04
AU2018364685A1 (en) 2020-03-26
PL3706710T3 (pl) 2024-08-05
FI3706710T3 (fi) 2024-07-08
WO2019092637A1 (en) 2019-05-16
IL305541A (en) 2023-10-01
KR20200087138A (ko) 2020-07-20
JP2021502337A (ja) 2021-01-28
IL274149A (en) 2020-06-30
AU2018364685B2 (en) 2021-05-20
CA3075722A1 (en) 2019-05-16
IL274149B1 (en) 2023-10-01
DK3706710T3 (da) 2024-07-08
BR112020008806A2 (pt) 2020-10-20
TWI813597B (zh) 2023-09-01
JP7284750B2 (ja) 2023-05-31
CL2020001156A1 (es) 2020-10-30
MX2020004477A (es) 2020-08-03
EP3706710A1 (en) 2020-09-16
TW201922245A (zh) 2019-06-16
RU2020115439A3 (enExample) 2021-12-10
ES2981903T3 (es) 2024-10-14
CN111278410A (zh) 2020-06-12
PT3706710T (pt) 2024-06-27
RS65659B1 (sr) 2024-07-31
EP3706710B1 (en) 2024-04-10
HRP20240808T1 (hr) 2024-09-27
SI3706710T1 (sl) 2024-08-30
RU2020115439A (ru) 2021-12-10

Similar Documents

Publication Publication Date Title
IL274149B2 (en) Sustained release formulations for intra-articular applications
WO2007035348A3 (en) Nanoparticulate aripiprazole formulations
WO2007086914A3 (en) Nanoparticulate clopidogrel formulations
RU2011115211A (ru) Стабилизированные фармацевтические субмикронные суспензии и способы их получения
ATE428401T1 (de) Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
PH12015502587A1 (en) Opthalmic nanoemulsion composition containing cyclosporine and method for preparing same
BRPI0506983A (pt) composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
MX2008014456A (es) Procedimiento para preparar microesferas para liberacion sostenida que tienen capacidad mejorada de dispersion y capacidad de inyeccion.
AR070824A1 (es) Suspensiones para inyeccion intravitrea de triamcinolona acetonido de baja viscosidad, altamente floculadas
RU2013122395A (ru) Фармацевтические составы для местного применения, содержащие низкую концентрацию бензоилпероксида в суспензии в воде и смешивающимся с водой органическом растворителе
US20090041843A1 (en) Pharmaceutical preparation having excellent photostability
WO2016193810A8 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
WO2012003003A3 (en) Methods for preparing nanoformulations and systems for nano - delivery using focused acoustics
JP2016513625A5 (enExample)
CA2535013A1 (en) Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
IL260229B2 (en) Suspension formulations of st-246 (tecovirimate monohydrate)
JP2014525402A5 (enExample)
JP2009196983A (ja) 眼科用組成物
JP2014534215A5 (enExample)
JP2021502337A5 (enExample)
EA200702518A1 (ru) Композиции на основе наночастиц и с контролируемым высвобождением, включающие цефалоспорин
TW201609109A (zh) 眼科用水性組成物
JP6333023B2 (ja) 水性医薬組成物
NZ584942A (en) Injectable meclizine formulations and methods comprising a molar excess of a modified cyclodextrin
JP2014525891A5 (enExample)